	US 12,144,998 B2
	Phototherapeutic light for treatment of pathogens
Nathan Stasko, Chapel Hill, NC (US); David T. Emerson, Durham, NC (US); Adam Cockrell, Durham, NC (US); F. Neal Hunter, Durham, NC (US); Michael John Bergmann, Atlanta, GA (US); Rebecca McDonald, Chapel Hill, NC (US); Nicholas William Medendorp, Jr., Raleigh, NC (US); Gerald H. Negley, Chapel Hill, NC (US); and Katelyn P. Reighard, Durham, NC (US)
Assigned to KNOW Bio, LLC, Morrisville, NC (US)
Filed by KNOW Bio, LLC, Durham, NC (US)
Filed on Jan. 13, 2021, as Appl. No. 17/148,108.
Application 17/148,108 is a division of application No. 17/117,858, filed on Dec. 10, 2020.
Application 17/117,858 is a continuation in part of application No. 16/898,385, filed on Jun. 10, 2020, granted, now 11,617,895.
Application 16/898,385 is a continuation of application No. 16/709,550, filed on Dec. 10, 2019, granted, now 11,524,173.
Application 16/709,550 is a continuation of application No. 15/222,199, filed on Jul. 28, 2016, granted, now 10,525,275.
Claims priority of provisional application 63/123,631, filed on Dec. 10, 2020.
Claims priority of provisional application 63/084,802, filed on Sep. 29, 2020.
Claims priority of provisional application 63/074,800, filed on Sep. 4, 2020.
Claims priority of provisional application 62/987,318, filed on Mar. 9, 2020.
Claims priority of provisional application 62/197,746, filed on Jul. 28, 2015.
Prior Publication US 2021/0128936 A1, May 6, 2021
Int. Cl. A61N 5/06 (2006.01); H01L 27/15 (2006.01)

CPC A61N 5/0613 (2013.01) [A61N 5/0601 (2013.01); A61N 5/0603 (2013.01); A61N 5/0624 (2013.01); H01L 27/15 (2013.01); A61N 2005/0611 (2013.01); A61N 2005/0626 (2013.01); A61N 2005/0647 (2013.01); A61N 2005/0652 (2013.01); A61N 2005/0653 (2013.01); A61N 2005/0661 (2013.01); A61N 2005/0662 (2013.01); A61N 2005/0663 (2013.01)]

22 Claims

1. A method comprising:

providing a first dose of light to mammalian tissue that induces a first biological effect for a first pathogen, the first dose of light being administered during a first time window, and an intensity of light of the first dose decreases to a reduced non-zero value during the first time window; and

providing a second dose of light to the mammalian tissue that induces a second biological effect, the second dose of light being administered during a second time window that is different than the first time window, wherein the second time window overlaps with a portion of the first time window, and wherein the first dose differs from the second dose by at least one of the following:

the first dose comprises a first peak wavelength in a range from 400 nanometers (nm) to 490 nm, the second dose comprises a second peak wavelength in a range from 500 nm to 900 nm or in a range from 320 nm to 400 nm, and the first peak wavelength is different than the second peak wavelength; or

the first dose comprises a first radiant flux in a range from 5 milliwatts per square centimeter (mW/cm²) to 10 mW/cm², the second dose comprises a second radiant flux in a range from 10 mW/cm²to 60 mW/cm², and the second dose is different than the first dose.